ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO0258

Health-Related Quality of Life in Roxadustat-Treated Patients with Anemia and Non-Dialysis-Dependent CKD

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism


  • Coyne, Daniel W., Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, United States
  • Manllo-Karim, Roberto, South Texas Kidney Specialists, P.A., McAllen, Texas, United States
  • Pergola, Pablo E., Renal Associates PA, San Antonio, Texas, United States
  • Pollock, Carol A., The University of Sydney, Sydney, New South Wales, Australia
  • Pecoits-Filho, Roberto, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Lee, Tyson T., FibroGen Inc, San Francisco, California, United States
  • Hardy, Elise, AstraZeneca, Gaithersburg, Maryland, United States
  • Yu, Kin-Hung Peony, FibroGen Inc, San Francisco, California, United States

Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and improves iron metabolism. Anemia in CKD impacts health-related quality of life (HRQL) by reducing physical capacity and energy levels. Studies have demonstrated a direct relationship between HRQL scores and hemoglobin (Hb) levels in non–dialysis-dependent (NDD) and dialysis-dependent patients with CKD. We assessed the impact of roxadustat on HRQL in patients with NDD-CKD.


Pooled data from three pivotal, phase 3, randomized, double-blind, placebo-controlled studies of roxadustat for the treatment of anemia in patients with NDD-CKD were assessed. Patients with data up to the time of dialysis treatment and who had pretreatment and ≥1 post-treatment HRQL measurement were included. Mean changes from baseline to Week 12 in HRQL scores were compared between the treatment groups.


Least-squares mean treatment differences favored the roxadustat group at Week 12 (all p-values <0.05) in the majority of measures analyzed (Table). Between-group differences were larger in subgroups with lower (ie, worse) baseline scores.


Roxadustat demonstrated improvement in most HRQL measures vs. placebo in patients with NDD-CKD.


  • Commercial Support –